AllergoOncology explores the intersection of allergic diseases and cancer, focusing on shared immune mechanisms mediated by monocytes and macrophages. These cells exhibit high heterogeneity, plasticity, and functional diversity across tissues and disease progression, yet their roles in allergic disorders remain unclear. This scoping review systematically analyzed 138 articles, identifying 451 molecules associated with monocyte and macrophage responses in allergic diseases, including Allergic Asthma, Atopic Dermatitis, and Allergic Rhinitis. Our findings revealed a research bias toward blood-derived samples, underrepresentation of tissue-resident macrophages and limited inclusion of non-coding RNAs. Semantic similarity and pathway enrichment analyses identified shared molecular signatures across major allergic disorders, highlighting interleukin signaling and immune activation pathways. Less-studied conditions, such as Allergic Alveolitis and Food Allergy, displayed distinct molecular profiles, emphasizing the need for broader investigations. To enhance data accessibility, we developed [ALO•HA](https://rebollidorioslab.shinyapps.io/aloha/), a web application for interactive analysis. [ALO•HA](https://rebollidorioslab.shinyapps.io/aloha/) fosters reproducibility and translational potential for both researchers and clinicians. Our findings highlight the need for integrative approaches, combining omics technologies and human-based studies, to better characterize monocyte and macrophage phenotypes in allergy. This work advances the understanding of allergy-immunity interactions, bridges allergy and oncology, addresses critical gaps and opens new opportunities for therapeutic development.

Background: We previously proposed the whey protein beta-lactoglobulin (BLG) loaded with iron-siderophore complexes as the active principle in the farm protective effect against allergies. A lozenge as food for specific medical purposes (FSMP) was formulated to assess its therapeutical efficacy in BALB/c mice and in-vitro experiments. Methods: Binding of iron-catechin into BLG was confirmed by spectroscopy and docking calculations. Serum IgE binding of children allergic to milk, or tolerating milk, was assessed to loaded (holo-) versus empty (apo-) BLG and for human mast cell degranulation. BLG and Bet v 1 double-sensitized mice were orally treated with the lozenge or placebo, and immunologically analysed after systemic allergen challenge. Human PBMCs of pollen allergic subjects were flow cytometrically assessed after stimulation with holoBLG in conjugation with catechin-iron complexes as ligands in a dietary supplement or with the apoBLG. Results: One major IgE- and T cell epitope were masked by catechin-iron complexes, which impaired IgE binding of milk allergic children and degranulation of mast cells. In mice, only supplementation with the lozenge reduced clinical reactivity to BLG and Bet v 1, promoted Tregs, and suppressed antigen presentation. In allergic subjects, stimulation of PBMCs with holoBLG led to a significant increase of intracellular iron in circulating CD14+ cells with significantly lower expression of HLADR and CD86 compared to their stimulation with apoBLG. Conclusion: The FSMP lozenge targeted antigen presenting cells and dampened immune activation in human immune cells and allergic mice in an antigen nonspecific manner, thereby conferring immune resilience against allergic symptoms.

Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype, and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment, and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune-glioma interactions to ultimately improve patient prognosis and survival.